Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview

Title:Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview

Volume: 17 Issue: 1

Author(s): Milunovic Vibor*, Inga Mandac Rogulj and Slobodanka Kolonic Ostojic

Affiliation:

• Lombardi Comprehensive Cancer Centre, Georgetown University, 3970 Reservoir Road NW E501, 20007 Washington D.C.,United States

Keywords: Immune thrombocytopenia, thrombopoietin receptor, romiplostim, eltrombopag, splenectomy.

Abstract: Background: Immune thrombocytopenia (ITP) in adulthood is characterized by chronic relapsing course. Despite the efficacious first line treatment (corticosteroid, intravenous immunoglobulin), majority of patients will enter the chronic phase warranting another treatment approach. Until recently, splenectomy performed in ITP chronic phase represented the standard of care with longterm remissions in more than 70% of patients, but it has never been tested in clinical trials. However, with the advances of our understanding of ITP pathophysiology and the shifting focus on megakaryocyte impairment, novel drugs were introduced in the treatment paradigm, mainly trombopoietin receptor agonists (TPO-RAs); romiplostim and eltrombopag.

Cite this article as:

Vibor Milunovic*, Rogulj Mandac Inga and Ostojic Kolonic Slobodanka, Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview, Cardiovascular & Hematological Disorders-Drug Targets 2017; 17 (1) . https://dx.doi.org/10.2174/1871529X16666161229155608